Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23557645 | 1.00 | KMT2A (0.51) | KMT2AALDH1A1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL12443041 | 0.89 | POLB (0.47) | KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL12002343 | 0.88 | KMT2A (0.50) | KMT2AALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL25664008 | 0.86 | KMT2A (0.48) | KMT2AALDH1A1POLB | |
| SCHEMBL25664007 | 0.86 | KMT2A (0.48) | KMT2AALDH1A1POLB | |
| SCHEMBL12000475 | 0.85 | KMT2A (0.48) | KMT2AALDH1A1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL12320825 | 0.85 | SLC6A1 (0.50) | ALDH1A1CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL7389564 | 0.85 | SLC6A1 (0.50) | ALDH1A1CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL30006184 | 0.85 | KMT2A (0.64) | KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1828277 | 0.81 | ALDH1A1 (0.46) | KMT2AALDH1A1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-10 | — | — | US | disclosed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | disclosed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | KMT2A 3133/4885ALDH1A1 434/4885SMN1; SMN2 4303/4885 |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | KMT2A 3133/4885ALDH1A1 434/4885SMN1; SMN2 4303/4885 |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | KMT2A 3120/4885ALDH1A1 428/4885SMN1; SMN2 4095/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | KMT2A 3120/4885ALDH1A1 428/4885SMN1; SMN2 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.